Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 16/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3677037 | 1.00 | LSS (0.61) | LSSNPC1L3MBTL1ALDH1A1THRB | |
| SCHEMBL8966193 | 0.82 | LSS (0.60) | LSSALDH1A1 | |
| SCHEMBL3684952 | 0.81 | LSS (0.62) | LSSNPC1 | |
| SCHEMBL3684949 | 0.81 | LSS (0.62) | LSSNPC1 | |
| SCHEMBL8903448 | 0.80 | NPC1 (0.48) | LSSNPC1L3MBTL1ALDH1A1THRB | |
| SCHEMBL8044544 | 0.80 | NPC1 (0.48) | LSSNPC1L3MBTL1ALDH1A1THRB | |
| SCHEMBL7677286 | 0.80 | LSS (0.73) | LSSL3MBTL1 | |
| SCHEMBL7677292 | 0.80 | LSS (0.73) | LSSL3MBTL1 | |
| SCHEMBL7767798 | 0.80 | LSS (0.60) | LSS | |
| SCHEMBL7679255 | 0.80 | LSS (0.60) | LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0636367-B1 | Use of phenylalkylamines for producing cholesterol lowering agents | HOFFMANN LA ROCHE (CH) | 2000-03-29 | — | — | EP | claimed |
| US-5495048-A | ANTICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | claimed |
| EP-0636367-A1 | Use of phenylalkylamines for producing cholesterol lowering agents | F. HOFFMANN-LA ROCHE AG (CH) | 1995-02-01 | — | — | EP | claimed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| EP-0636367-B1 | Use of phenylalkylamines for producing cholesterol lowering agents | HOFFMANN LA ROCHE (CH) | 2000-03-29 | — | — | EP | disclosed |
| US-5637771-A | Compound useful for lowering cholesterol | HOFFMANN-LA ROCHE INC. (US) | 1997-06-10 | — | — | US | disclosed |
| US-5574071-A | ADMINISTERING PHENYLALKYLAMINO KETONES | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5495048-A | ANTICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0636367-A1 | Use of phenylalkylamines for producing cholesterol lowering agents | F. HOFFMANN-LA ROCHE AG (CH) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | LSS 2247/4885NPC1 1892/4885L3MBTL1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.